External Partner Projects
Not Specified
Pre-clinical/DevelopmentActive
Key Facts
About Laxxon Medical
Laxxon Medical is a private, pre-revenue biotech firm developing a novel additive manufacturing platform (SPID®-Technology) for creating advanced oral dosage forms. Its business model focuses on three commercial solutions: patent extension for existing drugs, development of advanced patented generics, and new drug development, primarily leveraging the FDA's 505(b)(2) regulatory pathway. With a pipeline of 13 in-house assets and 4+ external projects, the company aims to capitalize on the impending patent cliff affecting over $100B in drug sales over the next decade.
View full company profileOther Not Specified Drugs
| Drug | Company | Phase |
|---|---|---|
| FL116 | Forlong Biotechnology | Not specified |
| FL117 | Forlong Biotechnology | Not specified |
| FL118 | Forlong Biotechnology | Not specified |
| FL301 | Forlong Biotechnology | Not specified |
| JSKN016 | AlphaMab Oncology | Phase 1 |
| JSKN033 | AlphaMab Oncology | Phase 1 |
| JSKN022 | AlphaMab Oncology | Phase 1 |
| JSKN027 | AlphaMab Oncology | Phase 1 |
| KN019 | AlphaMab Oncology | Phase 1 |
| New TCM Formulations | China SXT Pharmaceuticals | Research / Pre-clinical |
| Long-acting Leronlimab | CytoDyn | Preclinical |
| SR2162 | SIMR (Australia) Biotech | IND Approved |